Nerve growth factor induced farnesoid X receptor upregulation modulates autophagy flux and protects hepatocytes in cholestatic livers

Arch Biochem Biophys. 2020 Mar 30:682:108281. doi: 10.1016/j.abb.2020.108281. Epub 2020 Jan 27.

Abstract

Upregulation of nerve growth factor (NGF) in parenchymal hepatocytes has been shown to exert hepatoprotective function during cholestatic liver injury. However, the modulatory role of NGF in regulation of liver autophagy remains unclear. This study aimed to scrutinize the regulatory role of NGF in hepatic expression of farnesoid X receptor (FXR), a bile acid (BA)-activated nuclear receptor, and to determine its cytoprotective effect on BA-induced autophagy and cytotoxicity. Livers of human hepatolithiasis and bile duct ligation (BDL)-induced mouse cholestasis were used for histopathological and molecular detection. The regulatory roles of NGF in autophagy flux and FXR expression, as well as its hepatoprotection against BA cytotoxicity were examined in cultured hepatocytes. FXR downregulation in human hepatolithiasis livers showed positive correlation with hepatic NGF levels. NGF administration upregulated hepatic FXR levels, while neutralization of NGF decreased FXR expression in BDL-induced cholestatic mouse livers. In vitro studies demonstrated that NGF upregulated FXR expression, increased cellular LC3 levels, and exerted hepatoprotective effect in cultured primary rat hepatocytes. Conversely, autophagy inhibition abrogated NGF-driven cytoprotection under BA exposure, suggesting involvement of NGF-modulated auophagy flux. Although FXR agonistic GW4064 stimulation did not affect auophagic LC3 levels, FXR activity inhibition significantly potentiated BA-induced cytotoxicity and increased cellular p62/SQSTM1 and Rab7 protein in SK-Hep1 hepatocytes. Moreover, FXR gene silencing abolished the protective effect of NGF under BA exposure. These findings support that NGF modulates autophagy flux via FXR upregulation and protects hepatocytes against BA-induced cytotoxicity. NGF/FXR axis is a novel therapeutic target for treatment of cholestatic liver diseases.

Keywords: Autophagy; Bile acids; Cholestasis; Farnesoid X receptor; Hepatocytes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autophagy*
  • Cell Line, Tumor
  • Cholestasis / metabolism*
  • Cholestasis / pathology
  • Cytoprotection
  • Hepatocytes / cytology
  • Hepatocytes / metabolism*
  • Humans
  • Isoxazoles / pharmacology
  • Liver / metabolism*
  • Liver / pathology
  • Male
  • Mice
  • Mice, Inbred ICR
  • Nerve Growth Factor / metabolism*
  • Protective Agents / pharmacology
  • RNA-Binding Proteins / metabolism*
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction
  • Transcriptional Activation

Substances

  • FXR1 protein, human
  • FXR1 protein, rat
  • Fxr1h protein, mouse
  • Isoxazoles
  • NGF protein, human
  • Ngf protein, rat
  • Protective Agents
  • RNA-Binding Proteins
  • Nerve Growth Factor
  • GW 4064